← Back to Screener
Entera Bio Ltd. Ordinary Shares (ENTX)
Price$1.18
Value ScoreF
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-58.35%
Price vs S&P 500 (4W)-9.22%
VGM Score18.95
Market Capitalization$58.16M
All Metrics
Book Value / Share (Quarterly)$0.23
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-31.38%
Cash Flow / Share (Quarterly)$-0.20
Price vs S&P 500 (YTD)-47.33%
Gross Margin (TTM)4.04%
Net Profit Margin (TTM)-4525.11%
EPS (TTM)$-0.26
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)-35.28%
EPS (Annual)$-0.25
ROI (Annual)-87.31%
Gross Margin (Annual)0.00%
Net Profit Margin (5Y Avg)-9546.37%
Cash / Share (Quarterly)$0.09
ROA (Last FY)-71.53%
Revenue Growth TTM (YoY)-76.80%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-91.24%
Operating Margin (TTM)-4522.87%
Cash Flow / Share (Annual)$-0.16
P/B Ratio5.44x
P/B Ratio (Quarterly)4.84x
Net Income / Employee (Annual)$-571,900
EV / Revenue (TTM)242.27x
Net Interest Coverage (TTM)-407.33x
ROA (TTM)-74.79%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)6.94x
Quick Ratio (Quarterly)7.73x
3-Month Avg Trading Volume0.17M
52-Week Price Return-41.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.88
P/S Ratio (Annual)1384.82x
Asset Turnover (Annual)0.00x
52-Week High$3.22
Operating Margin (5Y Avg)-9584.75%
EPS Excl Extra (Annual)$-0.25
CapEx CAGR (5Y)16.43%
26-Week Price Return-50.42%
Quick Ratio (Annual)6.93x
13-Week Price Return-4.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.93x
Enterprise Value$54.03M
Revenue / Share Growth (5Y)-46.27%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-4.47%
Revenue / Employee (Annual)$2,100
Pretax Margin (Annual)-27235.71%
Cash / Share (Annual)$0.15
3-Month Return Std Dev97.29%
Gross Margin (5Y Avg)16.41%
Net Income / Employee (TTM)$-618,900
ROE (Last FY)-87.31%
Net Interest Coverage (Annual)-445.45x
EPS Basic Excl Extra (Annual)$-0.25
Receivables Turnover (TTM)0.67x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)0.67x
ROI (TTM)-87.97%
P/S Ratio (TTM)260.82x
Pretax Margin (5Y Avg)-9524.31%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.63
Price vs S&P 500 (52W)-65.66%
Year-to-Date Return-39.18%
5-Day Price Return-7.09%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-79.03%
Net Profit Margin (Annual)-27235.71%
Month-to-Date Return-12.59%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.25
Operating Margin (Annual)-27450.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-91.24%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)5.34x
P/B Ratio (Annual)6.79x
Pretax Margin (TTM)-4518.83%
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)-12.32%
Beta1.51x
Revenue / Share (TTM)$0.00
ROE (TTM)-87.97%
52-Week Low$0.91
vGradeF
gGradeF
mGradeD
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.07est. -0.15
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENTXEntera Bio Ltd. Ordinary Shares | F | F | D | $1.18 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Entera Bio is a clinical-stage biopharmaceutical company developing orally administered peptide therapeutics for chronic conditions, including osteoporosis and hypoparathyroidism. Its lead candidates are first-in-class mini tablet formulations of synthetic PTH (1-34) with tailored pharmacokinetic profiles, designed to offer patients a more convenient alternative to current injectable therapies.